Int J Psychiatry Clin Pract. 2000;4(1):77-80. doi: 10.1080/13651500050518442.
The recent advent of atypical antipsychotics has provided new clinical options and set higher expectations for the treatment of schizophrenia. Such agents might more effectively prevent relapse because they are more effective against the full spectrum of schizophrenic symptoms, as well as having improved tolerability and leading to improved medication compliance. Quetiapine fumarate ('Seroquel') is a new dibenzothiazepine antipsychotic agent with a greater affinity for serotonin receptors than for dopamine receptors and with a lower propensity for producing extrapyramidal symptoms or increasing prolactin levels. It has recently been approved for the treatment of psychotic disorders; however, the long-term efficacy and safety of quetiapine for treating treatment-refractory schizophrenia is still being investigated. We present a case of a 58-year-old man suffering from chronic therapy-resistant schizophrenia, with both positive and negative symptoms, who was successfully treated with quetiapine for 5 years. To the best of our knowledge, this is the first report of such long beneficial use of quetiapine in a hospital clinical practice. (Int J Psych Clin Pract 2000; 4:77-80).
最近出现的非典型抗精神病药物为治疗精神分裂症提供了新的临床选择，并提高了人们的期望。这些药物可能更有效地预防复发，因为它们对精神分裂症的所有症状都更有效，而且具有更好的耐受性，并提高了患者的服药依从性。富马酸喹硫平（“Seroquel”）是一种新型二苯并硫氮杂䓬类抗精神病药物，与多巴胺受体相比，它对 5-羟色胺受体具有更高的亲和力，并且产生锥体外系症状或增加催乳素水平的倾向较低。它最近已被批准用于治疗精神障碍；然而，喹硫平治疗难治性精神分裂症的长期疗效和安全性仍在研究中。我们报告了一例 58 岁的慢性治疗抵抗性精神分裂症患者，其既有阳性症状也有阴性症状，使用喹硫平治疗 5 年后症状得到了成功缓解。据我们所知，这是喹硫平在医院临床实践中首次有如此长期获益的报告。（Int J Psych Clin Pract 2000; 4:77-80）。
